With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...

It will be co-led by Patrizia Cavazzoni, director of the FDA's Centre for Drugs Evaluation and Research (CDER), and Centre for Biologics Evaluation and Research (CBER) director Peter Marks.

RBC Capital Markets adjusted its stance on Intra-Cellular Therapies shares, downgrading the biopharmaceutical company from Outperform to Sector Perform. The firm, however, raised its price target on ...

Brenner, who has worked in the FDA’s Center for Devices and Radiological Health, will lead the agency until a permanent ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

The FDA's decision followed a priority review and was based on positive outcomes from a randomized, double-blind, placebo-controlled study. Johnson & Johnson said the study demonstrated that ...

Coast Guard Commandant Adm. Linda Fagan was ousted by the Trump administration Tuesday, on President Trump's first full day in office. In 2022, Fagan became the first woman to lead a branch of the ...

The order is titled “Ending the Weaponization of the Federal Government,” but it asserts that the Biden administration might have acted illegally and directs agencies to seek evidence. By ...

Among the dozens of Biden-era executive orders he rescinded on day one, President Trump nixed one that aimed to explore new health care payment models that would lower prescription costs for ...